vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
Westrock Coffee Co is the larger business by last-quarter revenue ($339.5M vs $281.3M, roughly 1.2× Guardant Health, Inc.). Westrock Coffee Co runs the higher net margin — -6.6% vs -45.7%, a 39.0% gap on every dollar of revenue. On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs 39.4%). Westrock Coffee Co produced more free cash flow last quarter ($27.8M vs $-54.2M). Over the past eight quarters, Westrock Coffee Co's revenue compounded faster (32.8% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
GH vs WEST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $339.5M |
| Net Profit | $-128.5M | $-22.6M |
| Gross Margin | 64.6% | 11.5% |
| Operating Margin | -43.0% | -2.6% |
| Net Margin | -45.7% | -6.6% |
| Revenue YoY | 39.4% | 48.3% |
| Net Profit YoY | -15.8% | 8.3% |
| EPS (diluted) | $-1.01 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $339.5M | ||
| Q3 25 | $265.2M | $354.8M | ||
| Q2 25 | $232.1M | $280.9M | ||
| Q1 25 | $203.5M | $213.8M | ||
| Q4 24 | $201.8M | $229.0M | ||
| Q3 24 | $191.5M | $220.9M | ||
| Q2 24 | $177.2M | $208.4M | ||
| Q1 24 | $168.5M | $192.5M |
| Q4 25 | $-128.5M | $-22.6M | ||
| Q3 25 | $-92.7M | $-19.1M | ||
| Q2 25 | $-99.9M | $-21.6M | ||
| Q1 25 | $-95.2M | $-27.2M | ||
| Q4 24 | $-111.0M | $-24.6M | ||
| Q3 24 | $-107.8M | $-14.3M | ||
| Q2 24 | $-102.6M | $-17.8M | ||
| Q1 24 | $-115.0M | $-23.7M |
| Q4 25 | 64.6% | 11.5% | ||
| Q3 25 | 64.7% | 11.7% | ||
| Q2 25 | 65.0% | 14.7% | ||
| Q1 25 | 63.3% | 13.6% | ||
| Q4 24 | 61.6% | 16.6% | ||
| Q3 24 | 61.1% | 16.8% | ||
| Q2 24 | 59.1% | 19.9% | ||
| Q1 24 | 61.2% | 19.4% |
| Q4 25 | -43.0% | -2.6% | ||
| Q3 25 | -37.3% | -2.4% | ||
| Q2 25 | -45.9% | -5.3% | ||
| Q1 25 | -54.6% | -6.1% | ||
| Q4 24 | -62.4% | -4.3% | ||
| Q3 24 | -61.3% | -5.8% | ||
| Q2 24 | -56.8% | -7.9% | ||
| Q1 24 | -59.2% | -5.3% |
| Q4 25 | -45.7% | -6.6% | ||
| Q3 25 | -35.0% | -5.4% | ||
| Q2 25 | -43.0% | -7.7% | ||
| Q1 25 | -46.8% | -12.7% | ||
| Q4 24 | -55.0% | -10.7% | ||
| Q3 24 | -56.3% | -6.5% | ||
| Q2 24 | -57.9% | -8.5% | ||
| Q1 24 | -68.2% | -12.3% |
| Q4 25 | $-1.01 | $-0.22 | ||
| Q3 25 | $-0.74 | $-0.20 | ||
| Q2 25 | $-0.80 | $-0.23 | ||
| Q1 25 | $-0.77 | $-0.29 | ||
| Q4 24 | $-0.90 | $-0.26 | ||
| Q3 24 | $-0.88 | $-0.16 | ||
| Q2 24 | $-0.84 | $-0.20 | ||
| Q1 24 | $-0.94 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $49.9M |
| Total DebtLower is stronger | $1.5B | $444.1M |
| Stockholders' EquityBook value | $-99.3M | $-1.9M |
| Total Assets | $2.0B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $49.9M | ||
| Q3 25 | $580.0M | $34.0M | ||
| Q2 25 | $629.1M | $44.0M | ||
| Q1 25 | $698.6M | $33.1M | ||
| Q4 24 | $525.5M | $26.2M | ||
| Q3 24 | $585.0M | $22.4M | ||
| Q2 24 | $933.7M | $24.3M | ||
| Q1 24 | $1.0B | $12.6M |
| Q4 25 | $1.5B | $444.1M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $393.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $-1.9M | ||
| Q3 25 | $-354.5M | $11.4M | ||
| Q2 25 | $-305.5M | $18.2M | ||
| Q1 25 | $-250.8M | $71.4M | ||
| Q4 24 | $-139.6M | $97.5M | ||
| Q3 24 | $-60.1M | $110.3M | ||
| Q2 24 | $-1.6M | $81.5M | ||
| Q1 24 | $68.3M | $91.7M |
| Q4 25 | $2.0B | $1.2B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.5B | $1.1B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.6B | $1.1B | ||
| Q1 24 | $1.7B | $983.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.03× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $36.7M |
| Free Cash FlowOCF − Capex | $-54.2M | $27.8M |
| FCF MarginFCF / Revenue | -19.3% | 8.2% |
| Capex IntensityCapex / Revenue | 9.9% | 2.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $36.7M | ||
| Q3 25 | $-35.4M | $-26.6M | ||
| Q2 25 | $-60.3M | $-7.0M | ||
| Q1 25 | $-62.7M | $-22.1M | ||
| Q4 24 | $-64.5M | $2.8M | ||
| Q3 24 | $-51.1M | $-332.0K | ||
| Q2 24 | $-94.0M | $-23.7M | ||
| Q1 24 | $-30.3M | $8.0M |
| Q4 25 | $-54.2M | $27.8M | ||
| Q3 25 | $-45.8M | $-44.7M | ||
| Q2 25 | $-65.9M | $-27.5M | ||
| Q1 25 | $-67.1M | $-63.4M | ||
| Q4 24 | $-83.4M | $-15.4M | ||
| Q3 24 | $-55.3M | $-36.7M | ||
| Q2 24 | $-99.1M | $-59.9M | ||
| Q1 24 | $-37.2M | $-60.9M |
| Q4 25 | -19.3% | 8.2% | ||
| Q3 25 | -17.3% | -12.6% | ||
| Q2 25 | -28.4% | -9.8% | ||
| Q1 25 | -33.0% | -29.7% | ||
| Q4 24 | -41.3% | -6.7% | ||
| Q3 24 | -28.9% | -16.6% | ||
| Q2 24 | -55.9% | -28.7% | ||
| Q1 24 | -22.1% | -31.7% |
| Q4 25 | 9.9% | 2.6% | ||
| Q3 25 | 3.9% | 5.1% | ||
| Q2 25 | 2.4% | 7.3% | ||
| Q1 25 | 2.2% | 19.3% | ||
| Q4 24 | 9.4% | 7.9% | ||
| Q3 24 | 2.2% | 16.5% | ||
| Q2 24 | 2.9% | 17.4% | ||
| Q1 24 | 4.1% | 35.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
